Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
Affiliation
Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, ManchesterIssue Date
2023
Metadata
Show full item recordAbstract
NoneCitation
Moliner L, Spurgeon L, Califano R. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? ESMO open. 2023 Feb 13;8(2):100879. PubMed PMID: 36791668. Pubmed Central PMCID: PMC9958277 Myers Squibb, Roche, Merck Sharp & Dohme, Boehringer Ingelheim, Takeda, Bayer, Sanofi, Pharmamar, Lilly Oncology, Janssen, Amgen, and Novartis. All other authors have declared no conflicts of interest. Epub 2023/02/16. eng.Journal
ESMO OpenDOI
10.1016/j.esmoop.2023.100879PubMed ID
36791668Additional Links
https://dx.doi.org/10.1016/j.esmoop.2023.100879Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.esmoop.2023.100879